Ztalmy (Ganaxolone) Patent Expiration, LOE Window & CMS Spending
Ztalmy (Ganaxolone) by Immedica Ab: FDA Orange Book LOE 2042-09-30, 0 AB generics, $24.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Immedica Ab |
| FDA Application & Pathway | N215904 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2042-09-30 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $24.1M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $22.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.9% 2-yr change) |